NASDAQ:GRFS

Grifols Stock Forecast, Price & News

$17.57
-0.43 (-2.39 %)
(As of 06/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.36
$17.96
50-Day Range
$16.76
$18.94
52-Week Range
$14.81
$20.60
Volume700,999 shs
Average Volume805,610 shs
Market Capitalization$12.08 billion
P/E Ratio18.30
Dividend Yield0.11%
Beta0.59
30 days | 90 days | 365 days | Advanced Chart
Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter.


Grifols logo

About Grifols

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.38 out of 5 stars

Medical Sector

760th out of 2,105 stocks

Pharmaceutical Preparations Industry

377th out of 832 stocks

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 3.1 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Grifols (NASDAQ:GRFS) Frequently Asked Questions

Is Grifols a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Grifols stock.
View analyst ratings for Grifols
or view top-rated stocks.

What stocks does MarketBeat like better than Grifols?

Wall Street analysts have given Grifols a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Grifols wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Grifols' next earnings date?

Grifols is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Grifols
.

How were Grifols' earnings last quarter?

Grifols, S.A. (NASDAQ:GRFS) issued its quarterly earnings data on Tuesday, May, 4th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.22 by $0.01. The biotechnology company earned $1.43 billion during the quarter. Grifols had a net margin of 10.78% and a trailing twelve-month return on equity of 9.92%.
View Grifols' earnings history
.

How has Grifols' stock been impacted by COVID-19 (Coronavirus)?

Grifols' stock was trading at $20.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GRFS stock has decreased by 13.7% and is now trading at $17.57.
View which stocks have been most impacted by COVID-19
.

How often does Grifols pay dividends? What is the dividend yield for Grifols?

Grifols announced a semi-annual dividend on Wednesday, May 26th. Stockholders of record on Friday, June 4th will be paid a dividend of $0.4385 per share on Monday, June 14th. This represents a yield of 2.6%. The ex-dividend date is Thursday, June 3rd. This is a boost from Grifols's previous semi-annual dividend of $0.14.
View Grifols' dividend history
.

Is Grifols a good dividend stock?

Grifols pays an annual dividend of $0.02 per share and currently has a dividend yield of 0.11%. Grifols does not yet have a strong track record of dividend growth. The dividend payout ratio of Grifols is 1.63%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Grifols will have a dividend payout ratio of 1.28% next year. This indicates that Grifols will be able to sustain or increase its dividend.
View Grifols' dividend history.

When did Grifols' stock split? How did Grifols' stock split work?

Grifols shares split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly minted shares were payable to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of Grifols stock prior to the split would have 200 shares after the split.

Who are Grifols' key executives?

Grifols' management team includes the following people:
  • Mr. Raimon Grifols Roura, Co-CEO & Exec. Director (Age 57, Pay $1.39M)
  • Mr. Víctor Grífols Deu, Co-CEO & Exec. Director (Age 44, Pay $1.39M)
  • Mr. Alfredo Arroyo Guerra, CFO & VP (Age 63)
  • Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs
  • Ms. Nuria Pascual Lapeña, VP of Corp. Treasury & Investor Relations (Age 57)
  • Mr. David Ian Bell, Gen. Counsel & Chief Corp. Devel. Officer (Age 66)
  • Ms. Maria Teresa-Rioné Llano, VP of Corp. Communications (Age 55)
  • Mr. Mateo Florencio Borrás Humbert, Corp. VP & Chief HR Officer (Age 65)
  • Mr. Francisco Javier Jorba Ribes, Corp. VP and Pres of the Biological Industrial Group (Age 70)
  • Mrs. Montserrat Lloveras Calvo, Corp. VP and Director of Corp. Accounting & Reporting (Age 59)

What is Raimon Grifols and Victor Grifols Deu's approval rating as Grifols' CEO?

205 employees have rated Grifols CEO Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among Grifols' employees.

Who are some of Grifols' key competitors?

What other stocks do shareholders of Grifols own?

What is Grifols' stock symbol?

Grifols trades on the NASDAQ under the ticker symbol "GRFS."

Who are Grifols' major shareholders?

Grifols' stock is owned by a variety of institutional and retail investors. Top institutional investors include FIL Ltd (1.21%), Black Creek Investment Management Inc. (0.69%), Goldman Sachs Group Inc. (0.69%), UBS Group AG (0.60%), Janus Henderson Group PLC (0.54%) and Baillie Gifford & Co. (0.47%).

Which institutional investors are selling Grifols stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, FIL Ltd, CIBC Private Wealth Group LLC, Reilly Financial Advisors LLC, Capital International Investors, Baillie Gifford & Co., GABELLI & Co INVESTMENT ADVISERS INC., and Whitebox Advisors LLC.

Which institutional investors are buying Grifols stock?

GRFS stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Soditic Asset Management LLP, Optiver Holding B.V., Black Creek Investment Management Inc., JPMorgan Chase & Co., Brandes Investment Partners LP, Janus Henderson Group PLC, and Morgan Stanley.

How do I buy shares of Grifols?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Grifols' stock price today?

One share of GRFS stock can currently be purchased for approximately $17.57.

How much money does Grifols make?

Grifols has a market capitalization of $12.08 billion and generates $6.10 billion in revenue each year. The biotechnology company earns $706.57 million in net income (profit) each year or $1.23 on an earnings per share basis.

How many employees does Grifols have?

Grifols employs 24,000 workers across the globe.

Does Grifols have any subsidiaries?

The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L..

When was Grifols founded?

Grifols was founded in 1909.

What is Grifols' official website?

The official website for Grifols is www.grifols.com.

Where are Grifols' headquarters?

Grifols is headquartered at 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174.

How can I contact Grifols?

Grifols' mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at (493) 571-2200 or via email at [email protected]


This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.